- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04523896
HDR Brachytherapy Plus Stereotactic Ablative Prostate Radiotherapy for Patients With Intermediate and High-risk Prostate Cancer (BRAchySABR)
High-Dose-Rate Prostate Brachytherapy Combined With Stereotactic Ablative Prostate Radiotherapy for Patients Diagnosed With Intermediate and High-risk Prostate Cancer. Phase II Clinical Trial.
Dose escalation is nowadays a standard strategy in radiotherapy for prostate cancer. Besides, it is believed that due to the radiobiology characteristics of prostate cells (low alpha/beta ratio), the delivery of higher radiation doses per fraction could theoretically improve the efficacy of the treatment. In this context, the combination of prostate brachytherapy and external beam radiotherapy (EBRT) has proven to be the most effective method of dose escalation significantly improving disease control in randomized clinical trials. Unfortunately, this strategy is also associated with an increased risk of acute and late adverse events compared to conventional EBRT alone. It has been proposed that this increase in adverse events could be related to the use Low-Dose-Rate (LDR) brachytherapy and that High-Dose-Rate (HDR) brachytherapy (a more modern and accurate procedure) could reduce this risk.
On the other hand, Stereotactic Ablative Radiotherapy (SABR) is a high-precision radiation technique that allows the delivery of higher doses per fraction in fewer sessions, reducing the total treatment time.
The investigators hypothesized that the combination of two highly conformal radiation techniques (HDR brachytherapy and SABR) could be well tolerated, while reducing total treatment time and therefore improving patient quality of life.
This is a single arm Phase II clinical trial designed to test the feasibility, tolerability and impact on quality of life of the combination of High-Dose-Rate prostate brachytherapy and SABR for patients with intermediate and high-risk prostate cancer.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: David Büchser, MD
- Phone Number: 6232 +34946006000
- Email: david.buechsergarcia@osakidetza.eus
Study Locations
-
-
Bizkaia
-
Barakaldo, Bizkaia, Spain, 48903
- Recruiting
- Biocruces Bizkaia Health Research Institute/Cruces University Hospital
-
Contact:
- David Büchser, MD
- Phone Number: 6232 +34946006000
- Email: david.buechsergarcia@osakidetza.eus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of adenocarcinoma of the prostate.
Intermediate or high-risk disease (as per NCCN criteria):
- Intermediate risk:
- Clinical stage ≤ T2c
- Gleason score 7 and initial PSA ≤ 20 ng/ml.
Gleason score ≤ 6 and initial PSA > 10 and ≤ 20 ng/ml.
- High risk,at least one of the following:
- Clinical stage T3a-b.
- Gleason score 8-10.
- Initial PSA > 20 ng/ml.
- Life expectancy of more than 10 years
- Able and willing to complete Expanded Prostate Index Composite (EPIC) end EORTC questionnaires
- Eastern Cooperative Oncology Group (ECOG) of 0 - 2.
- Willing to give informed consent to participate in this clinical trial
- Give competent informed consent to participate in this trial.
Exclusion Criteria:
- Documented nodal or distant metastases.
- Previous pelvic radiotherapy.
- Clinical stage T4.
- Clinical stage T3a or T3b in which the coverture of the extraprostatic disease is not feasible (as deemed by the treating physician).
- Prostate volume > 70 cc (measured on MRI).
- Poor baseline urinary function defined as International Prostate Symptom Score (IPSS) >17
- Contra-indication to radical prostate radiotherapy
- Significant medical co-morbidity rendering patient unsuitable for general anaesthetic
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HDR brachytherapy + SABR
High-Dose-Rate prostate brachytherapy: a single fraction of 15 Gy to the whole prostate. Between 2-4 weeks after the brachytherapy session, SABR treatment will be delivered: 5 sessions of 5 Gy in consecutive days (i.e monday to friday) to a total dose of 25 Gy to the whole prostate. |
- Brachytherapy: Real time HDR prostate brachytherapy using a MRI-trans-rectal ultrasound image fusion protocol: single fraction of 15 Gy. Planning software: Oncentra prostate (Nucletron) - External beam radiotherapy: Stereotactic ablative radiation therapy (SABR): 5 session in 5 consecutive days, 5 Gy per fraction to the prostate. Intra-fraction gold seeds monitoring using Auto beam Hold solution (Varian) Planning software: Eclipse (Varian).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Deterioration of patient quality of life as assessed by EPIC-26 (The Expanded Prostate Cancer Index Composite short form)
Time Frame: 24 months
|
Impact on Quality of life affecting the genitourinary, gastrointestinal, sexual and hormonal domains using the EPIC-26 short form (graded from 0-100, with higher scores representing better quality of life).
Baseline value (i.e.
prior to treatment) will be compared to values recorded 1 month, 3 months, 12 months and 24 months after treatment.
|
24 months
|
Deterioration of patient quality of life as assessed by EORTC (European Organisation for Research and Treatment of Cancer) QLQ-PR25 short form.
Time Frame: 24 months
|
Impact on Quality of life affecting the genitourinary, gastrointestinal, sexual and hormonal domains using the EORTC QLQ-PR25 short form (items and scale scores of the QLQ-PR25 are linearly transformed to a 0-100 scale, with higher scores reflecting either more symptoms (urinary, bowel, hormonal treatment-related symptoms) or higher levels of functioning (sexual).).
Baseline value (i.e.
prior to treatment) will be compared to values recorded 1 month, 3 months, 12 months and 24 months after treatment.
|
24 months
|
Incidence and severity of genitourinary treatment-related acute adverse events graded according to CTCAE (Common Terminology Criteria for Adverse Events) v5.0 scale.
Time Frame: 3 months
|
Every urinary event occurring within 3 months from treatment completion will be defined as "acute event".
All adverse events will be recorded and graded according to CTCA V5.0 scale (graded from 0-5 with greater values representing worse outcomes)
|
3 months
|
Incidence and severity of gastrointestinal treatment-related acute adverse events graded according to CTCAE (Common Terminology Criteria for Adverse Events) v5.0 scale.
Time Frame: 3 months
|
Every gastrointestinal event occurring within 3 months from treatment completion will be defined as "acute event".
All adverse events will be recorded and graded according to CTCA V5.0 scale (graded from 0-5 with greater values representing worse outcomes)
|
3 months
|
Incidence and severity of genitourinary treatment-related late adverse events graded according to CTCAE (Common Terminology Criteria for Adverse Events) v5.0 scale.
Time Frame: 24 months months
|
Every genitourinary event occurring 3 months after treatment completion will be defined as "late event".
All adverse events will be recorded and graded according to CTCA V5.0 scale (graded from 0-5 with greater values representing worse outcomes) 6 months, 12 months and 24 months after treatment.
|
24 months months
|
Incidence and severity of gastrointestinal treatment-related late adverse events graded according to CTCAE (Common Terminology Criteria for Adverse Events) v5.0 scale.
Time Frame: 24 months months
|
Every gastro-intestinal event occurring 3 months after treatment completion will be defined as "late event".
All adverse events will be recorded and graded according to CTCA V5.0 scale (graded from 0-5 with greater values representing worse outcomes) 6 months, 12 months and 24 months after treatment.
|
24 months months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment efficacy in biochemical control measured through PSA (prostate specific antigen) level.
Time Frame: 24 months
|
PSA will be evaluated at baseline and in every follow-up visit (1 month, 3 months, 6 months, 12 months and 24 months after treatment completion.
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Büchser, MD, Biocruces Bizkaia Health Research Institute/ Cruces University Hospital
- Principal Investigator: Alfonso Gomez-Iturriaga, MD, PhD, Biocruces Bizkaia Health Research Institute/ Cruces University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BRAchySABR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasm
-
National Cancer Institute (NCI)CompletedProstatic Neoplasms | Prostate Cancer | Neoplasm, Prostate | Neoplasm,ProstaticUnited States
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterCompletedProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Neoplasm of Uncertain BehaviorUnited States
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
-
Advanced Accelerator ApplicationsTerminatedProstatic NeoplasmUnited States, Spain
-
Sismanoglio General HospitalNational and Kapodistrian University of AthensCompletedProstatic NeoplasmGreece
-
Sharp HealthCareCompleted
-
AHS Cancer Control AlbertaCross Cancer InstituteCompleted
-
Debiopharm International SACompletedProstatic NeoplasmSouth Africa
-
National Cancer Institute (NCI)CompletedProstatic NeoplasmUnited States
-
Centre Hospitalier Universitaire de BesanconRecruiting
Clinical Trials on Real time High-Dose-Rate prostate brachytherapy in combination with stereotactic prostate radiotherapy
-
British Columbia Cancer AgencyActive, not recruitingProstate CancerCanada
-
British Columbia Cancer AgencyBC Cancer FoundationRecruiting
-
British Columbia Cancer AgencyUniversity of British Columbia; Vancouver Prostate Centre; BC Cancer FoundationRecruitingLocalized Prostate CarcinomaCanada
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8United States
-
Centre Georges Francois LeclercRecruitingTo Evaluate the Rate of Digestive and Urinary ToxicityFrance
-
CHU de Quebec-Universite LavalRecruiting
-
N.N. Petrov National Medical Research Center of...RecruitingBiochemical Relapse Free Survival | Complications Rates (Erectile Dysfunction, GI, GU Complications)Russian Federation
-
British Columbia Cancer AgencyRecruitingOligometastatic Prostate CancerCanada
-
CHU de Quebec-Universite LavalSunnybrook Health Sciences Centre; Université de MontréalCompletedProstate CancerCanada
-
University Hospital, GrenobleClinical Investigation Centre for Innovative Technology Network; KoelisRecruiting